View clinical trials related to EGFR-TKI.
Filter by:Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors(EGFR-TKI)resistance will be treated with Apatinib and EGFR-TKI. The primary objective is the disease progression free survival of the patients.